 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys today announced a preclinical data presentation for E7777 denileukin diftitox, its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer SITC 35th Anniversary Annual Meeting, being held virtually. Dr. Anil Namboodiripad, Senior Vice President and Head of Dr. Reddys P 